SNC80

Names

[ Name ]:
SNC80

[Synonym ]:
(+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide
4-[(R)-[(2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide
SNC80
Benzamide, 4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propen-1-yl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethyl-
4-[(R)-[(2S,5R)-4-Allyl-2,5-dimethylpiperazin-1-yl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide
MFCD00672673
2-Pyridylethylamine dihydrochloride

Biological Activity

[Description]:

SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioid receptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment[1][2][3][4][5][6].

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Opioid Receptor

Signaling Pathways >> Neuronal Signaling >> Opioid Receptor

Research Areas >> Neurological Disease

[Target]

IC50: 2.73 nM (δ-opioid receptor), 5457 nM (μ-opioid receptor)[3] Ki: 1.78 nM (δ-opioid receptor), 881.5 nM (μ-opioid receptor) and 441.8 nM (κ-opioid receptor)[2]

[In Vitro]

SNC80 selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 exhibits substantially greater activity in cells coexpressing μ- and δ-opioid receptors than in cells either singly expressing δ-opioid receptors or coexpressing δ- and κ-opioid receptors[4].

[In Vivo]

SNC80 (10 mg/kg; intraperitoneal injection; once; C57BL6/J mice) treatment significantly attenuated this allodynia caused by overuse of Sumatriptan[1]. Animal Model: Male and female C57BL6/J mice (20-30g) injected with Sumatriptan[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; once Result: Significantly attenuated allodynia.

[References]

[1]. Moye LS, et al. Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology. 2019 Apr;148:77-86.

[2]. Bilsky EJ, et al. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther. 1995 Apr;273(1):359-66.

[3]. Calderon SN, et al. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J Med Chem. 1994 Jul 8;37(14):2125-8.

[4]. Metcalf MD, et al. The δ opioid receptor agonist SNC80 selectively activates heteromeric μ-δ opioid receptors. ACS Chem Neurosci. 2012 Jul 18;3(7):505-9.

[5]. Vicente-Sanchez A, et al. The delta opioid receptor tool box. Neuroscience. 2016 Dec 3;338:145-159.

[6]. Dripps IJ, et al. Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80. Br J Pharmacol. 2018 Mar;175(6):891-901.

Chemical & Physical Properties

[ Density]:
1.0±0.1 g/cm3

[ Boiling Point ]:
564.8±50.0 °C at 760 mmHg

[ Melting Point ]:
122-123ºC

[ Molecular Formula ]:
C₂₈H₃₉N₃O₂

[ Molecular Weight ]:
449.628

[ Flash Point ]:
295.4±30.1 °C

[ Exact Mass ]:
449.304230

[ PSA ]:
36.02000

[ LogP ]:
3.37

[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C

[ Index of Refraction ]:
1.545

MSDS

Click to get detail MSDS

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Articles

PKA and ERK1/2 are involved in dopamine D₁ receptor-induced heterologous desensitization of the δ opioid receptor.

Life Sci. 92(23) , 1101-9, (2013)

Chronic administration of cocaine attenuates delta opioid receptor (DOPR) signaling in the striatum and the desensitization is mediated by the indirect actions of cocaine on dopamine D1 receptors (D1R...

Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling.

J. Pharmacol. Exp. Ther. 344(1) , 179-88, (2013)

Drugs targeting G-protein-coupled receptors (GPCRs) make up more than 25% of all prescribed medicines. The ability of GPCRs to form heteromers with unique signaling properties suggests an entirely new...

Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety.

J. Pharmacol. Exp. Ther. 335(1) , 133-9, (2010)

Alcoholism and anxiety disorders have a huge impact on society and afflict 17.6 million and 40 million people in the United States, respectively. A strong comorbidity exists between alcoholism and anx...